VIR Vir Biotechnology, Inc.: institutional ownership and insider trading
260 funds reported holding $1.58B of Vir Biotechnology, Inc. in their latest 13F filings; in Q2 2026 funds net bought $74.4M, with 30 new positions and 44 funds selling out; over the last 12 months insiders bought $0 and sold $8.85M on the open market; over its last four quarters it reported revenue of $303M and net income of −$252M.
VIR revenue and earnings
- Quarter ended Jun 30, 2026: revenue $239M, net income $80.1M, EPS 0.47
- Quarter ended Mar 31, 2026: revenue −$29.0K, net income −$126M, EPS -0.85
- Quarter ended Dec 31, 2025: revenue $64.1M, net income −$42.9M, EPS -0.31
- Quarter ended Sep 30, 2025: revenue $240K, net income −$163M, EPS -1.17
Famous investors holding VIR
- Two Sigma (Two Sigma Investments): $11.3M, 0.0% of the portfolio
- Renaissance Technologies (Renaissance Technologies): $10.4M, 0.0% of the portfolio
- Ken Griffin (Citadel Advisors): $10.6M, 0.0% of the portfolio
- D. E. Shaw (D. E. Shaw & Co.): $4.24M, 0.0% of the portfolio
- Izzy Englander (Millennium Management): $489K, 0.0% of the portfolio
Largest institutional holders of VIR
- BlackRock, Inc. (BLK) — $211M
- ARCH Venture Management, LLC — $129M
- VANGUARD PORTFOLIO MANAGEMENT LLC — $117M
- SB INVESTMENT ADVISERS (UK) LTD — $112M
- STATE STREET CORP (STT, STT-PG) — $102M
- GSK plc (GSK, GLAXF) — $87.1M
- VANGUARD GROUP INC — $75.7M
- VANGUARD CAPITAL MANAGEMENT LLC — $65.1M
- Point72 Asset Management, L.P. — $57.7M
- GEODE CAPITAL MANAGEMENT, LLC — $34.1M
Recent VIR insider trades
- Jun 1, 2026: Sabatini Brent sold 379 shares ($3.58K)
- Jun 1, 2026: Napolitano Janet sold 3,200 shares ($30.2K)
- May 1, 2026: Sato Vicki L sold 22,000 shares ($221K)
- Apr 6, 2026: De Backer Marianne sold 72,559 shares ($665K)
5%+ owners
- Vanguard Portfolio Management: 6.9% (Schedule 13G/A, filed Jul 31, 2026)
- SB Investment Advisers (UK) Limited: 6.5% (Schedule 13G/A, filed May 15, 2026)
- STATE STREET CORPORATION: 5.9% (Schedule 13G, filed Aug 7, 2026)